|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Role of cytokines and chemokines in non-alcoholic fatty liver disease显示文摘Non-alcoholic fatty liver disease (NAFLD) includes a variety of histological conditions (ranging from liver steatosis and steatohepatitis, to fibrosis and hepatocarcinoma) that are characterized by an increased fat content within the liver. The accumulation/deposition of fat within the liver is essential for diagnosis of NAFLD and might be associated with alterations in the hepatic and systemic inflammatory state. Although it is still unclear if each histological entity represents a different disease or rather steps of the same disease, inflammatory processes in NAFLD might influence its pathophysiology and prognosis. In particular, non-alcoholic steatohepatitis (the most inflamed condition in NAFLDs, which more frequently evolves towards chronic and serious liver diseases) is characterized by a marked activation of inflammatory cells and the upregulation of several soluble inflammatory mediators. Among several mediators, cytokines and chemokines might play a pivotal active role in NAFLD and are considered as potential therapeutic targets. In this review, we will update evidence from both basic research and clinical studies on the potential role of cytokines and chemokines in the pathophysiology of NAFLD. | Vincent Braunersreuther Giorgio Luciano Viviani Franois Mach Fabrizio Montecucco | 2012 | World Journal of Gastroenterology2012，18，8： | 40 |
| 2 | Potential pathophysiological role for the vitamin D deficiency in essential hypertension显示文摘Vitamin D deficiency has been indicated as a pandemicemerging public health problem. In addition to the well-known role on calcium-phosphorus homeostasis in thebone, vitamin D-mediated processes have been recentlyinvestigated on other diseases, such as infections, can-cer and cardiovascular diseases. Recently, both the dis-covery of paracrine actions of vitamin D(recognized as'local vitamin D system') and the link of vitamin D with renin-angiotensin-aldosterone system and the fibroblast growth factor 23/klotho pathways highlighted its ac-tive cardiovascular activity. Focusing on hypertension, this review summarizes the more recent experimental evidence involving the vitamin D system and deficiency in the cardiovascular pathophysiology. In particular, we updated the vascular synthesis/catabolism of vitamin D and its complex interactions between the various endocrine networks involved in the regulation of blood pressure in humans. On the other hand, the conflicting results emerged from the comparison between obser-vational and interventional studies emphasize the frag-mentary nature of our knowledge in the field of vitamin D and hypertension, strongly suggesting the need of further researches in this field. | Federico Carbone Fran?ois Mach Nicolas Vuilleumier Fabrizio Montecucco | 2014 | World Journal of Cardiology2014，6，5： | 17 |
| 3 | Matrix metalloproteinase-9:A deleterious link between hepatic ischemia-reperfusion and colorectal cancer显示文摘Despite the advent of improved surgical techniques and the development of cytotoxic chemotherapeutic agents useful for the treatment of colorectal cancer,the primary clinical challenge remains that of preventing and combating metastatic spread.Surgical resection is the best treatment for colorectal metastases isolated to the liver.However,in rodent models,the hepatic ischemia-reperfusion(I/R) applied during the surgery accelerates the outgrowth of implanted tumors.Among the adverse effects of I/R on cellular function,several studies have demonstrated an over expression of the matrix metalloproteinase-9(MMP-9) in the ischemic liver.Since several studies showed high local levels of expression and activity of this proteolytic enzyme in the primary colorectal adenocarcinoma,the role of MMP-9 might be considered as a potential common mediator,favoring both growth of local tumor and the dissemination of colorectal carcinoma metastases. | Sébastien Lenglet Franois Mach Fabrizio Montecucco | 2012 | World Journal of Gastroenterology2012，18，48： | 6 |
| 4 | Autoantibodies to apolipoprotein A-1 as a biomarker of cardiovascular autoimmunity显示文摘Immune-driven inflammation plays an important part inatherogenesis and is therefore believed to be key to thedevelopment of cardiovascular disease(CVD), whichis currently the leading cause of death in the Westernworld. By fulfilling some of the Koch postulates, athero-genesis has even been proposed to be considered as anautoimmune disease, raising the hope that CVD couldbe prevented by immunomodulation. Nevertheless,the role of the immune system and autoimmune reac-tions in atherosclerosis appear to be a double edged-sword, with both pro-atherogenic and anti-atherogenicattributes. Hence, if immunomodulation is to becomea therapeutic option for atherosclerosis and CVD, it willbe crucial to correctly identify patients who might ben-efit from targeted suppression of deleterious autoim-mune responses. This could be achieved, for example, by the detection of disease-associated autoantibodies. In this work, we will review the currently available clini-cal, in vitro, and animal studies dedicated to autoan-tibodies against apolipoprotein A-1(anti-apoA-1 IgG), the major proteic fraction of high density lipoprotein. Current clinical studies indicate that high levels of anti-apoA-1 IgG are associated with a worse cardiovascular prognosis. In addition, in vitro and animal studies indi-cate a pro-inflammatory and pro-atherogenic role, sup-porting the hypothesis that these autoantibodies may play a direct causal role in CVD, and furthermore that they could potentially represent a therapeutic target for CVD in the future. | Nicolas Vuilleumier Fabrizio Montecucco Oliver Hartley | 2014 | World Journal of Cardiology2014，6，5： | 5 |
| 5 | Risk of hepatitis B virus reactivation in rheumatoid arthritis patients undergoing biologic treatment: Extending perspective from old to newer drugs显示文摘Hepatitis B virus(HBV) reactivation in rheumatoid arthritis(RA) patients undergoing biological therapy is not infrequent. This condition can occur in patients with chronic hepatitis B as well as in patients with resolved HBV infection. Current recommendations are mainlyfocused on prevention and management strategies of viral reactivation under tumor necrosis factor-α inhibitors or chimeric monoclonal antibody rituximab. In recent years, growing data concerning HBV reactivation in RA patients treated with newer biological drugs like tocilizumab and abatacept have cumulated. In this review, epidemiology, pathogenesis and natural history of HBV infection have been revised first, mainly focusing on the role that specific therapeutic targets of current biotechnological drugs play in HBV pathobiology; finally we have summarized current evidences from scientific literature, including either observational studies and case reports as well, concerning HBV reactivation under different classes of biological drugs in RA patients. Taking all these evidences into account, some practical guidelines for screening, vaccination, prophylaxis and treatment of HBV reactivation have been proposed. | Francesca De Nard Monica Todoerti Vittorio Grosso Sara Monti Silvia Breda Silvia Rossi Carlomaurizio Montecucco Roberto Caporali | 2015 | World Journal of Hepatology2015，7，3： | 3 |
| 6 | Left atrial thrombosis in an anticoagulated patient after bioprosthetic valve replacement:Report of a case显示文摘We present the case of a 74 year old woman suffering from severe mitral valve incompetence and rapid atrial fibrillation. After an appropriate vitamin K antagonist(VKA) therapy, the patient underwent mitral valve replacement by bioprosthesis. Then, the patient was rehospitalized for jaundice. Suspecting hepatotoxicity, VKA was discontinued and fondaparinux was started. During this treatment, the patient developed a symptomatic atrial thrombus. After exclusion of a hepatic disease, VKA was re-established with hemodynamic and liver enzymes normalization and atrial thrombus resolution. Caution has to be used when considering fondaparinux as an alternative strategy to VKA in patients with multiple thrombotic risk factors. | Gian Marco Rosa Antonello Parodi Ulrico Dorighi Federico Carbone Franois Mach Alessandra Quercioli Fabrizio Montecucco Nicolas Vuilleumier Manrico Balbi Claudio Brunelli | 2014 | World Journal of Clinical Cases2014，2，1： | 2 |
| 7 | Sofosbuvir/velpatasvir: A promising combination显示文摘Hepatitis C virus(HCV) affects 3% of the world population. It represents the main cause of chronic liver disease and is responsible for extra-hepatic complications, such as type 2 diabetes and cardiovascular diseases. HCV includes 7 genotypes differing in the nucleotide sequence variability, the geographic distribution, the rates of viral clearance, the risk of progression to liver fibrosis and to hepatocellular carcinoma, and the response to therapy. Last years have seen remarkable advances in the field of HCV infection with the approval of direct antiviral agents(DAAs) targeting key viral proteins involved in the HCV replication. Several oral regimens combining DAAs from different families have been developed and these regimens showed increased and sustained virological response rates to above 90% reducing the treatment duration to 12 wk or less. In particular, sofosbuvir, a nucleotide analogue nonstructural(NS)5B polymerase inhibitor, and velpatasvir, a NS5 A inhibitor, have been tested in two phase 3 trials, the ASTRAL-2(against HCV genotype 2) and the ASTRAL-3(against HCV genotype 3), demonstrating to be effective, safe, and well tolerated in patients who were 18 years of age or older and had at least a 6-mo history of HCV infection with a compensated liver disease. | Aldo Bonaventura Fabrizio Montecucco | 2016 | World Journal of Hepatology2016，8，19： | 2 |
| 8 | Virulence factors of Helieobaeter pylori显示文摘 | Dundon WG de Bernard M Montecucco C | 2001 | Int J Med Mierobiol2001，290，8： | 1 |
| 9 | Insulin resist- ance: a proinflammatory state mediated by lipid-in- duced signaling dysfunction and involved in atheroscle- rotic plaque instability显示文摘 | Montecucco F Steffens S Mach F | 2008 | Mediators Inflamm2008，2008，： | 1 |
| 10 | Statins inhibit C - reactive protein- induced chemokine secretion, ICAM - 1 upregulation and chemotaxis in adherent human monocytes显示文摘 | Montecucco F Burger F Pelli G | 2009 | Rheumatolo- gy2009，48，3： | 1 |
| 11 | Auto-antibodies as Emergent Prognostic Markers and Possible Mediators of Ischemic Cardiovascular Diseases显示文摘 | P. Roux-Lombard S. Pagano F. Montecucco N. Satta N. Vuilleumier | 2013 | Clinical Reviews in Allergy & Immunology2013，，1： | 1 |
| 12 | Molecular and cellular mechanisms of action of the vacuolating cytotoxin (VaA)and neutrophil-activating protein (HP-NAP) virulence factors of Helicobacter pylori显示文摘 | Montecucco C De Bernard M | 2003 | Microbes Infect2003，5，8： | 1 |
| 13 | CB(2) cannabinoid receptor activation is cardioprotective in a mouse model of ischemia/reperfusion显示文摘 | Montecucco F Lenglet S Braunersreuther V | 2009 | J Mol Cell Cardiol2009，46，5： | 1 |
| 14 | Neurotoxins affecting neuroexocytosis 显示文摘 | Schiavo G Matteoli M Montecucco C | 2000 | Physiol Rev2000，80，： | 1 |
| 15 | Role of Renin- Angiotensin system in inflammation, immunity and aging显示文摘 | Capettini LS Montecucco F Mach F | 2012 | Curt Pharm Des2012，18，7： | 1 |
| 16 | Atherosclerosis is an inflammatory disease显示文摘 | Montecucco F Mach F | 2009 | Semin Immunopathol2009，31，1： | 1 |
| 17 | Statins inhibit C-reactive protein-induced chemokine secretion,ICAM-1 upregulation and chemotaxis in adherent human monocytes显示文摘 | Montecucco F Burger F Pelli G | 2009 | Rheumatology(Oxford)2009，48，3： | 1 |
| 18 | The renin-angiotensinsystem modulates inflammatory processes in atheroscle-rosis :evidence from basic research and clinical studies显示文摘 | Montecucco F Pende A Mach F | 2009 | Mediators Inflamm2009，，75： | 1 |
| 19 | C-reactive protein (CRP) induces chemokine secretion via CDllb/ ICAM-1 interaction in human adherent monocytes显示文摘 | Montecucco F Steffens S Burger F | 2008 | J Leukoc Biol2008，84，4： | 1 |
| 20 | Nicotinamide phosphoribosyl transferase as a target in inflammation-relat- ed disorders显示文摘 | Montecucco F Cea M Cagnetta A | 2013 | Curr Top Med Chem2013，13，23： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员